Sirolimus DEB in Coronary Bifurcation Lesions
A Prospective, Multicenter, Randomized Controlled, Non-inferior Clinical Trial to Evaluate the Efficacy and Safety of Sirolimus Drug-eluting Coronary Balloon Catheter in Treatment of Coronary Bifurcation Lesions
Shenzhen Salubris Pharmaceuticals Co., Ltd.
280 participants
Mar 18, 2021
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of sirolimus drug-eluting coronary balloon catheter in treatment of coronary bifurcation lesions. This is a prospective, multicenter, randomized controlled, non-inferior clinical trial, which would enroll 280 participants in total. Paticipants would undergoing PCI with sirolimus DEB or paclitaxel DEB, and be followed-up to 24 months.
Eligibility
Inclusion Criteria8
- Male or Female that ages 18-85 year old;
- Having evidence of myocardial ischemia;
- Voluntarily participates in this study and signs the informed consent form (ICF);
- Sufficiently compliant with the study protocol and agreed to receive follow-up at 1 month ±7 days, 6 months ±14 days, 9 months ±30 days, 12 months ±30 days, and 24 months ±30 days, of which angiography was required at 9 months ±30 days;
- Angiography confirmed as de novo bifurcation lesion with side-branch stenosis (diameter) ≥70%;
- Suitable for PCI and side-branch lesions are not expected to stent implantation, and no drug-eluting balloon used for the main-branch. If a stent is implanted into the main-branch, it's usually necessary to perform a final balloon kissing on the two branches;
- Residual stenosis of the side-branch lesion ≦50% after pre-treatment, with a TIMI flow grade 3;
- The target vessel diameter was 2.0mm-4.0mm.
Exclusion Criteria16
- Women who is pregnant or lactating, or having a fertility plan within 1 year or are unwilling to take effective contraceptive measures;
- Cardiogenic shock patients;
- With hemorrhagic symptoms or active gastrointestinal ulcers, or previous stroke within 6 months, or who are expected to be unable to tolerate double-antibody therapy after interventional therapy;
- ST-segment elevation myocardial infarction (STEMI) occurred within one week before enrollment;
- With severe congestive heart failure or NYHA class Ⅳ heart failure;
- With severe valvuar heart disease;
- Heart transplant patients;
- With renal insufficiency (creatinine \> 3.0mg/ dL or 265.2 umol /L) and/or advanced renal disease requiring dialysis;
- With a life expectancy less than 1 year;
- With contraindications who cannot take aspirin and/or clopidogrel and/or ticagrelor;
- With known allergies to paclitaxel, sirolimus, contrast agents, etc.;
- Participating in clinical trials of other drugs or devices and has not met the primary endpoint;
- Non-target lesions cannot be processed before the target lesions or non-target lesions treatment fails;
- Intra-stent restenosis;
- High-risk left main disease;
- Other patients considered by the investigator to be unsuitable for inclusion.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients in experimental group will undergo PCI, using sirolimus drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
Patients in control group will undergo PCI, using paclitaxel drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04896177